Wockhardt share price today

Wockhardt Ltd's share price was ₹1,947.00 at the close on 6 November 2026. It has been rising for 24 weeks. That is 9.1% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,176 and ₹2,266, and at that close it sat 71% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Wockhardt Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 11 weeks in a row.

Over the last 11 years the share price moved +117% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: operating margin up 11 points on a year earlier, profit up on a year earlier for 4 quarters in a row and number of shareholders up 25% in a year.

1. Operating margin up 11 points on a year earlier

   21% in the June 2026 quarter, from 10%.

2. Profit up on a year earlier for 4 quarters in a row

   In the June 2026 quarter profit was ₹107 crore, +199.1% on a year earlier.

3. Number of shareholders up 25% in a year

   1,73,116 shareholders in the September 2026 quarter, against 1,37,946 a year earlier.

For April to June 2026 (the quarter ended 30 June 2026), Wockhardt reported revenue of ₹929 crore, up 25.9% from ₹738 crore a year earlier, and a profit of ₹107 crore, against a loss of ₹108 crore a year earlier.

Wockhardt results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

The newest call in our records is from 4 June 2026, about January to March 2026; a call about these results is not in our records yet.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Wockhardt closed at ₹1,947.00 on 6 November 2026, up 45.5% from ₹1,337.70 a year earlier (7 November 2025) and up 379.5% over five years. Its highest weekly close since March 2016 was ₹2,266.40 on 25 September 2026.

Wockhardt share price: then and now

Weekly closing prices. Each change is the move from that price to the 6 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

563 weekly closes from 11 March 2016 to 6 November 2026.

6 Nov 2026: Wockhardt closed at ₹1,947.00, up 2.7% on the week and down 2.5% on the month. Results for April to June 2026: Revenue up 25.9% on a year earlier.

Earlier

• Our read, 14 Jun 2026: A decade-long R&D bet on novel antibiotics is finally delivering, Zaynic FDA approval creates a $1.5-2B peak sales path, while FY26 profitability and 19% operating margin prove the base business has structurally recovered.
• 4 Jun 2026: Wockhardt held its results call for January to March 2026. Management guided: Zaynic launch in India within current fiscal year.

Our read of the business

FY26 closes at profit ₹199 Cr (first profitable full year since FY22) on revenue ₹3,373 Cr and operating profit 19%, a 1,300 basis points margin recovery driven by product mix shift away from generics toward specialty biosimilars and novel antibiotics now at 23% of business.,Zaynic (WCK-5222) received FDA approval June 2026, the first Indian company-discovered drug approved by US FDA, with Phase 3 showing 96.8% composite cure rate vs Meropenem and peak global revenue guidance of $1.5-2 billion; the US commercial launch is underway with a 12-18 month slow ramp to breakeven.,Second growth leg is diabetes biosimilars (27% FY26 growth, doubling capacity in 12-15 months) in a market with only 6-7 competitors, with the UK business at 39% of revenue and 13% growth providing stable earnings base while NCE revenues ramp.

Latest quarter: Best quarter on record, operating margin 23%, profit ₹164 Cr, revenue +29.9% on a year earlier closes FY26 as first profitable year since FY22.

Our read after the latest results, written 14 June 2026.

Wockhardt has paid no dividend on the NSE since 1 April 2021, the start of the period we checked.

Not in its latest year. Wockhardt Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 2 of its last 13 reported years, so there is a history but no current dividend.

From the NSE corporate-actions record, read 7 November 2026.

On the call for January to March 2026, held on 4 June 2026, Wockhardt's management guided: Zaynic launch in India within current fiscal year.

“For many years, investors asked us when the investment in research, biotech, and innovation would begin to translate into growth. We believe that moment has arrived”Dr. Murtaza Khorakiwala, Managing Director, on the call for January to March 2026

What management guided

• European regulatory approval for Zaynic planned end-of-year.
• Novel antibiotic segment operating breakeven expected 12-18 months post-launch.
• Zaynic peak global annual revenue $1.5-2 billion.
• Biosimilar business to double size within 24-36 months.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for January to March 2026, 4 June 2026. The April to June 2026 results are out since, so this part may be out of date until we update it.

What is changing at Wockhardt, from the latest results and calls: zaynic (wck-5222), fda approved, us commercial launch underway, biosimilar platform, 27% growth + capacity doubling and miqnaf + emrok, novel antibiotic base revenue.

• Zaynic (WCK-5222), FDA Approved, US Commercial Launch Underway. FDA approval received; US commercial launch with experienced team (ex-Shionogi CCO) underway; 12-18 month hockey-stick ramp to segment breakeven; peak global revenue $1.5-2B guided. ⚠ estimate
• Biosimilar Platform, 27% Growth + Capacity Doubling. Biosimilar business grew 27% FY26; insulin 2x, glargine 1.5x capacity; plan to double business in 24-36 months; 6-7 competitors vs 15-20 in MoAbs creates pricing headroom. ⚠ estimate
• Miqnaf + EMROK, Novel Antibiotic Base Revenue. Miqnaf: first new macrolide in 35 years, launched May 2025; EMROK: 100K patients, ~10% market share, two validated specialty commercial channels. ⚠ estimate
• UK + Emerging Markets Core Business Stability. UK 39% of revenue, 13% growth, top-5 market position; EM 28% of revenue, 45% on a year earlier growth via strategic partnerships in FY26. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown.

Our read after the latest results, written 14 June 2026.

Cash conversion cycle expanded 108 days from FY22 to FY26; primary driver is payables compression (from 265 to 182 days); inventory days also rising to 286 days, signals capacity build for biosimilar ramp.

The main risks

• Working capital bloating, CCC expanded from 60 to 168 days: Cash conversion cycle expanded 108 days from FY22 to FY26; primary driver is payables compression (from 265 to 182 days); inventory days also rising to 286 days, signals capacity build for biosimilar ramp. ✓ fact
• Miqnaf and EMROK specialist channel validation at scale: Wockhardt is transitioning from generics distribution to specialist antibiotic commercialization, EMROK at 10% market share is proof of concept, but Miqnaf + Zaynic parallel launches test whether the organization can execute two specialist launches simultaneously. ✓ fact

Our read after the latest results, written 14 June 2026.

When Wockhardt reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Zaynic US commercial launch execution clarity: leadership team staffing velocity versus plan, early hospital system partnership announcements, initial formulary coverage placements by academic medical centers - roadmap to 12-18 month segment breakeven requires visible initial adoption signals.

Wockhardt is on 2 of our India lists: Small & mid cap stocks and Pharma stocks.

Wockhardt Ltd earned ₹107 Cr of net profit in the Jun 2026 quarter. Full-year FY26 profit was ₹199 Cr. Over 10 years profit has grown −2.3% a year on average. That is 11.5% of the quarter's revenue. The same quarter a year earlier lost ₹108 Cr. 7 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

Wockhardt Ltd reported ₹929 Cr of revenue in the Jun 2026 quarter, +25.9% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 10 years it has grown −2.7% a year on average. The last full year, FY26, came in at ₹3,373 Cr.

Revenue is everything the company billed its customers in the period.

Why this happened. Zaynic received FDA approval, first Indian company-discovered drug approved by US FDA, per June 2026 concall (C045). Phase 3 showed 96.8% composite cure rate and 90% micro-cure vs Meropenem (C056). US commercial team is in place: CCO from Shionogi Fetroja launch, CMO from Boston hospital system, 3PL distribution partner (C055). Focus on academic medical centers with high-resistance Gram-negative patient populations. US adoption trajectory: 12-18 month slow ramp as infectious disease specialists learn the molecule, then material acceleration (C057). UK NHS subscription model (up to GBP 20M/year for 3 years independent of volume) de-risks revenue during ramp (C052). European regulatory…

The last four reported quarters add to ₹3,564 Cr.

FY26 revenue was ₹3,373 Cr, +12.0% on the year before.

Recent pace: the last four quarters grew +18.9% on average, against −2.7% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +18.4%, against +11.0% a year over the last 8 quarters (accelerating).

Wockhardt Ltd's operating margin was 21.0% in the Jun 2026 quarter, 11.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between −2.3% and 21.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +10.9 percentage points on the year while gross margin changed +1.3 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 5% of Wockhardt Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹390 Cr of operating cash against ₹199 Cr of profit. After ₹628 Cr of spending on assets, free cash was −₹238 Cr: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 5% of profit came in as cash: the cash cycle got 11 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page.

What to look at next: less of the profit turns into cash than it should, and the cash cycle is 11 days longer. The next section looks at where the cash is stuck.

Wockhardt Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 168 days in FY26, up from 157 days in FY21. It spent ₹1,256 Cr on assets over the last 3 years. Customers take 64 days to pay, and stock sits for 286 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹3,373 Cr, each day of that cycle ties up about ₹9.2 Cr, so roughly ₹1,553 Cr is tied up in the business at any time.

FY26: customers took 64 days to pay and stock sat for 286 days, about 9.4 months of sales sitting as stock, for a full cycle of 168 days, longer than FY21's 157.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 286 days. Customers pay about 64 days after that. Suppliers are paid at 182 days. Together that makes the 168-day cycle.

Spending on assets: ₹1,256 Cr over the last 3 years, against ₹667 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹2,379 Cr (FY26): assets paid for that are not earning yet.

In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit.

Wockhardt Ltd's P/E is 79.4×, near the low end of its own history: it has been lower only 33% of the time. Its usual P/E (the middle reading) is 90.0×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹25.17.